MYL9 and adrenal cortex carcinoma: In the analysis of clinicopathological characteristics, MYL9 expression was closely related to the tumor TNM stage in bladder urothelial carcinoma, adrenocortical carcinoma, stomach adenocarcinoma, and thyroid carcinoma (Figure S1B).